Related Experiment Video

Updated: Aug 26, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K

[Mechanism Underlying the Inhibitory Effect of MiR-532-3p on the Cells Proliferation of Diffuse Large B-Cell

Yan Zhang1, Qian Yao1, Jian-Jun Jin1

  • 1The First School of Clinic Medicine, Lanzhou University; Lanzhou 730000, Gansu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|October 8, 2022
PubMed
Abstract

Insights

This study shows that increasing miR-532-3p levels and using resibufogenin (RES) can inhibit the growth of diffuse Large B-cell lymphoma (DLBCL) cells by affecting Wnt/β-catenin signaling. Both strategies show promise in targeting lymphoma cell proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Diffuse Large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
  • The Wnt/β-catenin signaling pathway plays a critical role in the pathogenesis and progression of various cancers, including DLBCL.
  • Identifying novel therapeutic targets and agents for DLBCL is crucial.

Purpose of the Study:

  • To investigate the therapeutic potential of miR-532-3p and resibufogenin (RES) in DLBCL.
  • To elucidate the underlying mechanism involving the regulation of Wnt/β-catenin signaling by miR-532-3p and RES in DLBCL cells.
  • To assess the impact of these interventions on DLBCL cell proliferation.

Main Methods:

  • Analysis of miR-532-3p expression in DLBCL tissues and adjacent normal tissues.
  • In vitro experiments using SU-DHL-4 cells treated with miR-532-3p mimics and resibufogenin (RES).
  • Detection of miR-532-3p expression via RT-qPCR, β-catenin protein levels via Western blot, and cell proliferation via MTT assay.

Main Results:

  • miR-532-3p expression was significantly downregulated in DLBCL tissues and cells compared to normal controls.
  • Overexpression of miR-532-3p significantly reduced SU-DHL-4 cell viability and decreased β-catenin expression.
  • RES treatment inhibited DLBCL cell proliferation and suppressed β-catenin expression.

Conclusions:

  • Overexpression of miR-532-3p effectively inhibits DLBCL cell proliferation by suppressing the Wnt/β-catenin signaling pathway.
  • Resibufogenin (RES) demonstrates anti-proliferative effects on lymphoma cells, partly through the inhibition of Wnt/β-catenin signaling.
  • Both miR-532-3p and RES represent potential therapeutic strategies for DLBCL.
Keywords:
Wnt/β-catenindiffuse large B-cell lymphomamiR-532-3presibufogenin

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.3K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K